These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32982608)

  • 1. Efficacy and Safety of Nicorandil in Preventing Contrast-Induced Nephropathy after Elective Percutaneous Coronary Intervention: A Pooled Analysis of 1229 Patients.
    Yi B; Mo S; Jiang Y; Yi D; Luo J; Chen X; Rong J
    J Interv Cardiol; 2020; 2020():4527816. PubMed ID: 32982608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
    Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
    Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
    Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
    Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicorandil improves clinical outcomes in patients with stable angina pectoris requiring PCI: a systematic review and meta-analysis of 14 randomized trials.
    Li Y; Liu H; Peng W; Song Z
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):855-865. PubMed ID: 30079778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial.
    Yusuf J; Prakash G; Safal S; Mehta V; Mukhopadhyay S
    Coron Artery Dis; 2024 May; 35(3):186-192. PubMed ID: 38411168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicorandil Reduces the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography/Intervention - Systematic Review and Meta-Analysis of Randomized Controlled Trials Including GRADE Qualification.
    Pranata R; Vania R; Alkatiri AA; Firman D; Lukito AA
    Cardiovasc Revasc Med; 2020 Sep; 21(9):1121-1127. PubMed ID: 31959562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
    Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Oral Nicorandil to Prevent Contrast-Induced Nephropathy in Patients with Chronic Renal Dysfunction Undergoing an Elective Coronary Procedure.
    Fan Z; Li Y; Ji H; Jian X
    Kidney Blood Press Res; 2019; 44(6):1372-1382. PubMed ID: 31639790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial.
    Zhang W; Dai J; Zheng X; Xu K; Yang X; Shen L; Wang X; Hao Z; Qiu X; Jiang L; Shi H; Shen L; He B
    Medicine (Baltimore); 2021 Apr; 100(15):e25551. PubMed ID: 33847683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive Effects of Nicorandil Against Contrast-Induced Nephropathy in Patients With Moderate Renal Insufficiency Undergoing Percutaneous Coronary Intervention.
    Zhang P; Li WY; Yang SC; Fu NK; Liu XG; Zhang X; Cong HL; Lin WH; Tian FS; Lu CZ; Zhang J
    Angiology; 2020 Feb; 71(2):183-188. PubMed ID: 30987432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mitochondrial ATP-sensitive potassium channel activation (nicorandil) in patients with angina pectoris undergoing elective percutaneous coronary interventions: A meta-analysis of randomized controlled trials.
    Zhu H; Xu X; Fang X; Zheng J; Chen T; Huang J
    Medicine (Baltimore); 2019 Jan; 98(3):e14165. PubMed ID: 30653160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Nicorandil Administration on Preventing Contrast-Induced Nephropathy: A Meta-Analysis.
    Zhan B; Huang X; Jiang L; Bao H; Cheng X
    Angiology; 2018 Aug; 69(7):568-573. PubMed ID: 28950711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effect of nicorandil on perioperative myocardial protection in patients undergoing elective PCI: A Systematic Review and Meta-Analysis.
    Ye Z; Su Q; Li L
    Sci Rep; 2017 Mar; 7():45117. PubMed ID: 28322321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of remote ischemia or nicorandil on myocardial injury following percutaneous coronary intervention in patients with stable coronary artery disease: A randomized controlled trial.
    Miyoshi T; Ejiri K; Kohno K; Nakahama M; Doi M; Munemasa M; Murakami M; Takaishi A; Kawai Y; Sato T; Sato K; Oka T; Takahashi N; Sakuragi S; Mima A; Enko K; Hosogi S; Nanba S; Hirami R; Nakamura K; Ito H;
    Int J Cardiol; 2017 Jun; 236():36-42. PubMed ID: 28214082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicorandil for Periprocedural Myocardial Injury in Elective Percutaneous Coronary Intervention: A Meta-Analysis of 10 Randomized Controlled Trials.
    Yi B; Luo J; Jiang Y; Mo S; Xiao X; Chen X; Rong J
    Angiology; 2020 Aug; 71(7):609-615. PubMed ID: 32295385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.
    Geng N; Ren L; Xu L; Zou D; Pang W
    BMC Cardiovasc Disord; 2021 Oct; 21(1):488. PubMed ID: 34629058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Nicorandil effectively attenuates the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: a randomized, controlled, open-label clinical trial.
    Abdollahi Moghaddam A; Baradaran Rahimi V; Morovatdar N; Rezaee R; Babalhekam SA
    Int Urol Nephrol; 2023 Sep; 55(9):2327-2334. PubMed ID: 36881267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive effect of nicorandil on contrast-induced nephropathy: a meta-analysis of randomised controlled trials.
    Li S; Wang L; Liu Y; Hu Q
    Intern Med J; 2018 Aug; 48(8):957-963. PubMed ID: 29740934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The periprocedural myocardial damage prevention during elective percutaneous coronary intervention as a result of pharmacological preconditioning with an oral form of nicorandil in patients with stable coronary artery disease. Pilot study.
    Gostishchev RV; Soboleva GN; Samko AN; Rogoza AN; Minasyan AA
    Ter Arkh; 2018 Sep; 90(9):53-59. PubMed ID: 30701736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.